What Are the Worst Side Effects of Wegovy?

Wegovy (semaglutide 2.4 mg) carries a range of side effects that span from persistently uncomfortable to genuinely dangerous. The most common problems are gastrointestinal: nausea, vomiting, diarrhea, and constipation hit a large share of users, especially during dose escalation. But the side effects that worry physicians most are rarer and more severe, including pancreatitis, gallbladder disease, a possible link to certain eye conditions, and emerging questions about psychiatric effects. Some of these risks are still being studied, and the picture has shifted as millions more people have started using the drug.

Nausea, Vomiting, and Other Gut Problems

The side effects you are most likely to experience on Wegovy are gastrointestinal. Nausea is far and away the top complaint, followed by vomiting, diarrhea, and constipation. These are generally the worst during the first weeks at each new dose level and tend to ease as your body adjusts. A review of adverse effects across GLP-1 receptor agonists confirmed that these gut symptoms remain the most common category, and that they are typically transient and tied to the dose.¹

For most people, these symptoms are unpleasant but manageable. For a meaningful minority, though, they are bad enough to quit the drug entirely. In one clinical-practice study of patients who discontinued semaglutide or tirzepatide, about 15% stopped specifically because they could not tolerate the side effects.² That number may sound small, but it represents people whose nausea, vomiting, or other symptoms were severe enough that losing the drug’s weight-loss benefits felt like the better trade.

Gastroparesis and Severe Stomach Slowing

Wegovy works partly by slowing how fast your stomach empties. For most users, that translates into feeling full longer. But in some cases, the slowing goes too far, effectively paralyzing normal stomach contractions. This condition, gastroparesis, can cause persistent nausea, vomiting, bloating, and abdominal pain that does not resolve on its own while the drug remains in your system.

A published case report described a 48-year-old woman with type 2 diabetes who developed persistent nausea and vomiting after resuming semaglutide at a high dose without following the recommended gradual dose-escalation schedule. She had jumped straight to 2 mg weekly instead of starting at the lowest dose and titrating up. Her gastroparesis resolved after stopping semaglutide and receiving treatment, but the case underscores a real danger of skipping dose steps.³ If you are restarting Wegovy after a break, your prescriber should walk you back through the titration, not pick up where you left off.

Pancreatitis

Acute pancreatitis, a sudden and painful inflammation of the pancreas, is one of the most medically serious risks linked to Wegovy. The connection between GLP-1 drugs and pancreatitis has been debated for years, but the evidence has grown more convincing. A pharmacovigilance analysis found that semaglutide was associated with a reporting odds ratio of about 19 for pancreatitis, meaning the signal in adverse-event databases was very strong. A separate population-based study found that patients who had used a GLP-1 receptor agonist within the prior 30 days were over twice as likely to be hospitalized for acute pancreatitis compared to non-users, with an adjusted odds ratio of 2.24. The risk remained elevated even for exposures up to two years prior.⁴

Pancreatitis symptoms include severe upper abdominal pain, often radiating to the back, along with nausea and vomiting. Anyone on Wegovy who develops this kind of pain should seek medical attention quickly. People with a history of pancreatitis are generally advised to avoid GLP-1 drugs entirely.

Gallbladder Disease

Rapid weight loss from any cause raises the risk of gallstones, and Wegovy is no exception. GLP-1 receptor agonists have been linked to an increased risk of both gallstone formation and gallbladder inflammation, particularly with prolonged use and higher doses.⁵ A meta-analysis looking specifically at semaglutide in people with obesity (without diabetes) found that the drug increased gallstone-related disorders by over 2.6 times compared to placebo.⁶

Gallbladder problems can range from asymptomatic stones found incidentally on imaging to cholecystitis requiring emergency surgery. Symptoms to watch for include sudden pain in the upper right abdomen, especially after eating fatty foods, sometimes accompanied by fever or jaundice. If you have had your gallbladder removed, this particular risk does not apply to you, but it is a genuine concern for everyone else on the drug.

Eye and Vision Risks

A less-discussed but increasingly concerning side effect involves the eyes. Several studies have now linked semaglutide to a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION), a condition where blood flow to the optic nerve is disrupted, causing sudden, painless vision loss in one eye. NAION is rare in the general population, and it remains rare among semaglutide users, but the relative increase is hard to ignore.

A large Danish cohort study of over 424,000 people with type 2 diabetes found that semaglutide users had more than double the five-year risk of NAION compared to non-users, with a hazard ratio of about 2.2 even after adjusting for other risk factors.⁷ A separate study using U.S. claims data found a similar pattern: among people with type 2 diabetes taking semaglutide or tirzepatide, NAION occurred at roughly 0.04% over two years, compared to 0.02% in a matched comparison group. Other optic nerve disorders were also elevated.⁸

For people with diabetes specifically, there is also a risk that rapid improvements in blood sugar can worsen existing diabetic retinopathy, including progression to proliferative disease and new-onset macular edema.⁹ The absolute numbers here are small, but NAION causes irreversible vision loss, which makes even a modest relative increase worth knowing about. Anyone who experiences sudden changes in vision while on Wegovy should be evaluated urgently.

Mental Health Concerns

The question of whether Wegovy affects mood and mental health has become one of the most debated topics surrounding the drug. Regulatory agencies in Europe and the United States have investigated reports of suicidal ideation among GLP-1 receptor agonist users, and the data so far paint a complicated picture.

A pharmacovigilance study that analyzed individual case safety reports submitted to the European drug-safety database found that among psychiatric adverse events linked to semaglutide, liraglutide, and tirzepatide, depression was the most commonly reported event, followed by anxiety and suicidal ideation.¹⁰ A separate analysis of the U.S. FDA’s adverse event reporting system found statistically significant signals for both depression and suicide or self-injury events specifically with semaglutide, but not with tirzepatide.¹¹

A large retrospective cohort study added more weight to the association, finding that GLP-1 receptor agonist users had roughly double the rate of psychiatric outcomes (including major depression, anxiety, and suicidal ideation) compared to non-users over follow-up periods from six months to five years.¹² These studies rely on adverse-event databases and retrospective data, which cannot prove that the drug caused these psychiatric events. People with obesity already have higher baseline rates of depression, and the emotional and social complexities of major weight loss add further confounding. Still, the consistency of the signal across multiple data sources means this is something prescribers should be discussing openly. If you have a history of depression or suicidal ideation, flagging that before starting Wegovy is important.

Hair Loss

Noticeable hair shedding has become one of the more talked-about side effects among Wegovy users, even though it was not heavily featured in early clinical trial data. The predominant type reported is telogen effluvium, which is a temporary but sometimes dramatic shedding that occurs when the body undergoes physical stress, including rapid weight loss. A systematic review found that hair loss linked to semaglutide appeared to be dose-dependent: doses under 2 mg weekly were rarely implicated, while the higher obesity-treatment doses (like Wegovy’s 2.4 mg) were more commonly associated with it. Women appeared to be disproportionately affected.¹³

A cohort study confirmed elevated odds of telogen effluvium with semaglutide use at three- and five-year follow-up points.¹⁴ The good news is that telogen effluvium is generally reversible once weight stabilizes. The hair follicles are not damaged; they are temporarily pushed into a resting phase. But for someone already self-conscious about their appearance during a major body change, losing clumps of hair can be distressing in a way that clinical reassurances about “transient” shedding do not fully capture.

Facial Volume Loss and “Ozempic Face”

Rapid fat loss does not happen only where you want it to. The face, which relies on subcutaneous fat pads to maintain a youthful contour, can lose volume faster than the skin can adapt. The result has been colloquially named “Ozempic face,” though it applies equally to Wegovy users since both drugs are semaglutide. A review of the phenomenon described it as involving collagen and elastin loss, fat and muscle volume reduction in facial tissue, and excessive skin sagging, all contributing to a prematurely aged appearance.¹⁵

This is not a dangerous side effect in a medical sense, but it is one that many users find deeply unwelcome and did not anticipate. The cosmetic-dermatology field has seen a surge in patients seeking dermal fillers and other treatments specifically to address facial hollowing caused by GLP-1 drugs. If you are losing weight rapidly, incorporating resistance training and ensuring adequate protein intake may help preserve some facial muscle volume, though the fat pad loss is harder to counteract.

Lean Mass Loss and Body Composition

Beyond the face, the broader concern about body composition centers on how much of the weight lost on Wegovy comes from muscle versus fat. A study tracking body composition changes on semaglutide found that total fat mass dropped by about 19% over 12 months, but lean mass also decreased significantly, falling by about 3 kg over the first seven months before stabilizing. Encouragingly, the proportion of lean mass relative to total body mass actually increased over time, meaning the body was losing fat faster than muscle.¹⁶

That stabilization of lean mass after the initial drop is reassuring, but 3 kg of lost muscle is not trivial, especially for older adults who are already at risk of sarcopenia. Resistance exercise during treatment is the most evidence-supported strategy for preserving muscle. If you are sedentary and relying entirely on the drug for weight loss, the proportion of muscle in your losses will likely be higher.

Surgical and Anesthesia Complications

One of the more practically important side effects has nothing to do with the drug itself in everyday life, but becomes critical if you need surgery. Because Wegovy slows gastric emptying, standard pre-surgery fasting instructions may not be enough to ensure your stomach is empty. A narrative review of perioperative management noted that gastric contents may not reliably clear even after 8 to 12 hours of fasting, particularly with long-acting weekly formulations. Case reports have described unexpected solid food residues found during anesthesia induction, sometimes with regurgitation.¹⁷

The concern is aspiration, where stomach contents enter the lungs during anesthesia. Most anesthesiology societies now recommend either holding Wegovy before elective surgery (typically for at least one dosing cycle) or performing a bedside gastric ultrasound to check for retained food. If you have any procedure coming up that involves sedation or general anesthesia, tell your anesthesiologist that you are on Wegovy. This applies to everything from colonoscopies to emergency surgery.

Thyroid Cancer and the Black Box Warning

Wegovy carries an FDA boxed warning about thyroid C-cell tumors, including medullary thyroid carcinoma. This warning exists because animal studies in rodents showed an increased incidence of these tumors with semaglutide. In humans, the evidence has been more reassuring so far. A systematic literature review that pooled data across 10 studies found that thyroid cancer incidence among semaglutide users was very low, with only isolated cases of papillary and medullary thyroid cancer, each accounting for less than 1% of study participants.¹⁸

The practical upshot: if you or a close family member has a history of medullary thyroid carcinoma or a rare genetic condition called multiple endocrine neoplasia type 2, Wegovy is contraindicated. For everyone else, the boxed warning reflects a precautionary principle based on animal data rather than a demonstrated human risk at this point. That said, these are the kinds of risks that can take decades of population-level exposure to confirm or rule out.

Reproductive Safety and Pregnancy Timing

Wegovy is not approved for use during pregnancy, and animal data suggest potential fetal harm. The practical challenge is that semaglutide has a long half-life of about seven days, meaning it lingers in the body well after the last injection. Current guidance recommends stopping semaglutide at least two months before attempting conception to allow the drug to fully clear.¹⁹ A more pharmacokinetically specific recommendation puts the minimum at about 35 days (five half-lives) before conception.²⁰

There is an added wrinkle: weight loss itself can improve fertility, sometimes quickly and unexpectedly. Women who had not been ovulating regularly may resume ovulation on Wegovy before they are ready to conceive. If you are of reproductive age and not planning pregnancy, reliable contraception while on Wegovy is worth discussing with your prescriber, and the two-month washout period before trying to conceive should be part of any preconception plan.

Hypoglycemia

Semaglutide on its own has a relatively low risk of causing dangerously low blood sugar, because its insulin-stimulating effect is glucose-dependent. But when combined with other diabetes medications, particularly insulin or sulfonylureas, the risk rises. A post-marketing surveillance analysis found that semaglutide did meet the statistical threshold for a hypoglycemia signal, though it ranked lower in risk compared to several other GLP-1 drugs like lixisenatide and exenatide.²¹ For people using Wegovy purely for weight management (without diabetes medications), hypoglycemia is unlikely to be a problem. For those on concurrent diabetes therapy, dose adjustments to the other drugs are often necessary.

Injection Site Reactions and Allergic Responses

Like any injectable medication, Wegovy can cause reactions at the injection site, including redness, swelling, and itching. More rarely, hypersensitivity reactions including anaphylaxis have been reported.²² True anaphylaxis is extremely uncommon, but anyone who has had a serious allergic reaction to semaglutide or any of its inactive ingredients should not use the drug. Mild injection site reactions tend to improve with rotating injection sites and are not usually a reason to stop treatment.

What Happens When You Stop

Stopping Wegovy is not exactly a side effect of taking it, but the rebound that follows discontinuation is something every user should understand before starting. In the STEP 1 trial extension, participants who stopped semaglutide after 68 weeks regained about two-thirds of their lost weight within the following year.²³ Most of the cardiometabolic improvements they had gained, like better blood pressure and blood sugar, also drifted back toward baseline.

A meta-analysis covering 11 randomized trials of GLP-1 receptor agonists in people with overweight or obesity found average weight regain of about 5.6 kg after stopping, along with increases in waist circumference, BMI, blood pressure, and blood sugar markers.²⁴ A narrative review confirmed that this rebound appears to happen regardless of how long someone was on treatment.²⁵ The implication is stark: for most people, Wegovy works only as long as you keep taking it. That reframes every side effect discussion, because you are weighing not just short-term tolerability but a potentially indefinite commitment to the drug and its risks.